跳至主要内容
临床试验/NCT02137538
NCT02137538已完成4 期

Randomization to Letrozole vs. Anastrozole in Short Pubertal Males

Stanford University1 个研究点 分布在 1 个国家目标入组 79 人开始时间: 2009年11月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
79
试验地点
1
主要终点
Predicted Adult Height at Year 3

研究概览

简要总结

The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
10 Years 至 17 Years(Child)
性别
Male
接受健康志愿者

入选标准

  • Current height less than 5th percentile AND/OR
  • Predicted adult height (based on bone age) more than 10 cm below target height (mid parental height)
  • Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl

排除标准

  • Bone age reading more than 14.0 years
  • Follicle stimulating hormone > 20 IU/L

研究组 & 干预措施

Letrozole

Active Comparator

Letrozole 2.5 mg daily

干预措施: Letrozole (Drug)

Anastrozole

Active Comparator

Anastrozole 1 mg daily

干预措施: Anastrozole (Drug)

结局指标

主要结局

Predicted Adult Height at Year 3

时间窗: Year 3

Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment. Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age).

次要结局

  • Estrone(Baseline, year 3)
  • Follicle Stimulating Hormone(Baseline, year 3)
  • Serum Testosterone(Baseline, year 3)
  • Androstenedione(Baseline, year 3)
  • Dihydrotestosterone(Baseline, year 3)
  • Luteinizing Hormone(Baseline, year 3)
  • Estradiol(Baseline, year 3)
  • Number of Adverse Events Related to Acne or Bone Fracture(3 years)
  • Insulin-like Growth Factor Type 1(Baseline, year 3)
  • Inhibin B(Baseline, year 3)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Laura K Bachrach

Professor of Pediatrics

Stanford University

研究点 (1)

Loading locations...

相似试验